{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:04:06Z","timestamp":1793829846758,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Selective nuclear export inhibitor selinexor (SEL) represents a promising therapeutic strategy for relapsed\/refractory multiple myeloma (RRMM). But its mechanisms of action as well as factors that influence therapeutic responses have not been fully characterized yet. In this study we employed catTFRE proteomics technique to profile changes in nuclear abundance of activated transcription factors (TFs)\/co-factors (TCs) in myeloma cells following SEL treatment. We found that pharmacological inhibition of exportin-1 (XPO1) by SEL leads to a significant nuclear accumulation of Lipin1 in NCI-H929 cells. Nuclear-localized Lipin1 acted as a transcriptional cofactor that suppressed the transcriptional activity of SREBPs. By performing subcellular localization analysis, molecular docking, co-immunoprecipitation and other assays, we demonstrated that Lipin1 was subjected to XPO1-dependent nuclear export. We demonstrated that SEL downregulated the expression of key lipogenesis-related genes regulated by SREBPs including FASN, SCD, DHCR24 and FDPS, leading to reduced fatty acid and cholesterol synthesis in MM cell lines and primary CD138<jats:sup>+<\/jats:sup> cells. Using shRNA-mediated knockdown assays, we elucidated the critical role of Lipin1 in mediating the inhibitory effects of SEL on the SREBPs pathway and its contribution to SEL sensitivity both in vitro and in murine xenograft models. In conclusion, we reveal a novel mechanism by which SEL downregulates cellular lipid biosynthesis, thereby inhibiting the proliferation of myeloma cells. This study highlights the critical role of Lipin1 in the anti-myeloma effects of SEL, suggesting its potential as a biomarker for identifying patients who are most likely to benefit from SEL-based therapies.<\/jats:p>","DOI":"10.1038\/s41401-025-01553-3","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:53:14Z","timestamp":1744617194000},"page":"2496-2508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma"],"prefix":"10.1038","volume":"46","author":[{"given":"Jun-ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-xing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ke","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-yu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"1553_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"1553_CR2","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Terpos E, Dimopoulos MA. How I treat relapsed multiple myeloma. Blood. 2022;139:2904\u201317.","journal-title":"Blood"},{"key":"1553_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40259-021-00514-6","volume":"36","author":"S Richard","year":"2022","unstructured":"Richard S, Jagannath S. Targeting nuclear export proteins in multiple myeloma therapy. BioDrugs. 2022;36:13\u201325.","journal-title":"BioDrugs"},{"key":"1553_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100758","volume":"46","author":"K Benkova","year":"2021","unstructured":"Benkova K, Mihalyova J, Hajek R, Jelinek T. Selinexor, selective inhibitor of nuclear export: unselective bullet for blood cancers. Blood Rev. 2021;46:100758.","journal-title":"Blood Rev"},{"key":"1553_CR5","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1002\/ajh.26434","volume":"97","author":"S Delimpasi","year":"2022","unstructured":"Delimpasi S, Mateos MV, Auner HW, Gavriatopoulou M, Dimopoulos MA, Quach H, et al. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: subgroup analysis from the BOSTON study. Am J Hematol. 2022;97:e83\u201386.","journal-title":"Am J Hematol"},{"key":"1553_CR6","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1002\/ajh.26010","volume":"96","author":"R Cornell","year":"2021","unstructured":"Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, et al. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021;96:e5\u20138.","journal-title":"Am J Hematol"},{"key":"1553_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02305-4","volume":"20","author":"L Qiu","year":"2022","unstructured":"Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, et al. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med. 2022;20:108.","journal-title":"BMC Med"},{"key":"1553_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13:61.","journal-title":"J Hematol Oncol"},{"key":"1553_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1-from biology to targeted therapy. Nat Rev Clin Oncol. 2021;18:152\u201369.","journal-title":"Nat Rev Clin Oncol"},{"key":"1553_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155\u201365.","journal-title":"Leukemia"},{"key":"1553_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","volume":"7","author":"GL Gravina","year":"2014","unstructured":"Gravina GL, Senapedis W, Mccauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85.","journal-title":"J Hematol Oncol"},{"key":"1553_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/jca.7080","volume":"4","author":"JG Turner","year":"2013","unstructured":"Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer. 2013;4:614\u201325.","journal-title":"J Cancer"},{"key":"1553_CR13","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7:78896\u2013909.","journal-title":"Oncotarget"},{"key":"1553_CR14","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1158\/0008-5472.CAN-17-1323","volume":"77","author":"F Conforti","year":"2017","unstructured":"Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez JA, et al. Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. Cancer Res. 2017;77:5614\u201327.","journal-title":"Cancer Res"},{"key":"1553_CR15","doi-asserted-by":"publisher","first-page":"26028","DOI":"10.1021\/jacs.3c06179","volume":"145","author":"WJ Gibson","year":"2023","unstructured":"Gibson WJ, Sadagopan A, Shoba VM, Choudhary A, Meyerson M, Schreiber SL. Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation. J Am Chem Soc. 2023;145:26028\u201337.","journal-title":"J Am Chem Soc"},{"key":"1553_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110418","volume":"38","author":"NB Nataraj","year":"2022","unstructured":"Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, et al. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Rep. 2022;38:110418.","journal-title":"Cell Rep"},{"key":"1553_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1615\/CritRevEukaryotGeneExpr.2019026309","volume":"29","author":"AF Ajayi-Smith","year":"2019","unstructured":"Ajayi-Smith AF, Van Der Watt PJ, Leaner VD. Interfering with nuclear transport as a means of interrupting transcription factor activity in cancer. Crit Rev Eukaryot Gene Expr. 2019;29:413\u201324.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"1553_CR18","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1217657110","volume":"110","author":"C Ding","year":"2013","unstructured":"Ding C, Chan DW, Liu W, Liu M, Li D, Song L, et al. Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements. Proc Natl Acad Sci USA. 2013;110:6771\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1553_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19694-w","volume":"11","author":"L Song","year":"2020","unstructured":"Song L, Liu Z, Hu HH, Yang Y, Li TY, Lin ZZ, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun. 2020;11:5842.","journal-title":"Nat Commun"},{"key":"1553_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","volume":"86","author":"D Eberl\u00e9","year":"2004","unstructured":"Eberl\u00e9 D, Hegarty B, Bossard P, Ferr\u00e9 P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86:839\u201348.","journal-title":"Biochimie"},{"key":"1553_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","volume":"146","author":"TR Peterson","year":"2011","unstructured":"Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin1 localization to control the SREBP pathway. Cell. 2011;146:408\u201320.","journal-title":"Cell"},{"key":"1553_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanh\u00e4usser","year":"2011","unstructured":"Schwanh\u00e4usser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473:337\u201342.","journal-title":"Nature"},{"key":"1553_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41401-020-00539-7","volume":"42","author":"L Tie","year":"2021","unstructured":"Tie L, Xiao H, Wu DL, Yang Y, Wang P. A brief guide to good practices in pharmacological experiments: Western blotting. Acta Pharmacol Sin. 2021;42:1015\u20137.","journal-title":"Acta Pharmacol Sin"},{"key":"1553_CR24","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/s41596-020-0312-x","volume":"15","author":"Y Yan","year":"2020","unstructured":"Yan Y, Tao H, He J, Huang SY. The HDOCK server for integrated protein-protein docking. Nat Protoc. 2020;15:1829\u201352.","journal-title":"Nat Protoc"},{"key":"1553_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31501-2","volume":"13","author":"S Feng","year":"2022","unstructured":"Feng S, Rastogi C, Loker R, Glassford WJ, Tomas Rube H, Bussemaker HJ, et al. Transcription factor paralogs orchestrate alternative gene regulatory networks by context-dependent cooperation with multiple cofactors. Nat Commun. 2022;13:3808.","journal-title":"Nat Commun"},{"key":"1553_CR26","doi-asserted-by":"publisher","first-page":"e00866","DOI":"10.1128\/mBio.00866-19","volume":"10","author":"M Gruffaz","year":"2019","unstructured":"Gruffaz M, Yuan H, Meng W, Liu H, Bae S, Kim JS, et al. CRISPR-Cas9 screening of kaposi\u2019s sarcoma-associated herpesvirus-transformed cells identifies XPO1 as a vulnerable target of cancer cells. mBio. 2019;10:e00866\u201319.","journal-title":"mBio"},{"key":"1553_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39854-y","volume":"14","author":"W Zhou","year":"2023","unstructured":"Zhou W, Wang W, Liang Y, Jiang R, Qiu F, Shao X, et al. The RNA-binding protein LRPPRC promotes resistance to CDK4\/6 inhibition in lung cancer. Nat Commun. 2023;14:4212.","journal-title":"Nat Commun"},{"key":"1553_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-023-01649-4","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q. Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther. 2023;8:425.","journal-title":"Signal Transduct Target Ther"},{"key":"1553_CR29","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, Mcneil B, et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus. Clin Cancer Res. 2016;22:6142\u201352.","journal-title":"Clin Cancer Res"},{"key":"1553_CR30","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1158\/1078-0432.CCR-15-0408","volume":"21","author":"F Conforti","year":"2015","unstructured":"Conforti F, Wang Y, Rodriguez JA, Alberobello AT, Zhang YW, Giaccone G. Molecular pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling. Clin Cancer Res. 2015;21:4508\u201313.","journal-title":"Clin Cancer Res"},{"key":"1553_CR31","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1111\/bph.15653","volume":"178","author":"G Xu","year":"2021","unstructured":"Xu G, Huang S, Peng J, Gao X, Li M, Yu S, et al. Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors. Br J Pharmacol. 2021;178:4741\u201357.","journal-title":"Br J Pharmacol"},{"key":"1553_CR32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/bioinformatics\/btu826","volume":"31","author":"D Xu","year":"2015","unstructured":"Xu D, Marquis K, Pei J, Fu SC, Ca\u011fatay T, Grishin NV, et al. LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins. Bioinformatics. 2015;31:1357\u201365.","journal-title":"Bioinformatics"},{"key":"1553_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s13238-020-00753-3","volume":"12","author":"J Xiao","year":"2021","unstructured":"Xiao J, Xiong Y, Yang LT, Wang JQ, Zhou ZM, Dong LW, et al. POST1\/C12ORF49 regulates the SREBP pathway by promoting site-1 protease maturation. Protein Cell. 2021;12:279\u201396.","journal-title":"Protein Cell"},{"key":"1553_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","journal-title":"Cancer Treat Rev"},{"key":"1553_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2217\/fon-2020-0054","volume":"16","author":"S Richard","year":"2020","unstructured":"Richard S, Richter J, Jagannath S. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma. Future Oncol. 2020;16:1331\u201350.","journal-title":"Future Oncol"},{"key":"1553_CR36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11427-017-9175-2","volume":"60","author":"X Li","year":"2017","unstructured":"Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci. 2017;60:1093\u2013113.","journal-title":"Sci China Life Sci"},{"key":"1553_CR37","doi-asserted-by":"crossref","unstructured":"K\u0131rl\u0131 K, Karaca S, Dehne HJ, Samwer M, Pan KT, Lenz C, et al. A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. Elife.2015;4:e11466.","DOI":"10.7554\/eLife.11466"},{"key":"1553_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13046-021-01886-x","volume":"40","author":"V Zuco","year":"2021","unstructured":"Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, et al. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. J Exp Clin Cancer Res. 2021;40:83.","journal-title":"J Exp Clin Cancer Res"},{"key":"1553_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30686-1","volume":"8","author":"VV Subhash","year":"2018","unstructured":"Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, et al. Anti-tumor efficacy of selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep. 2018;8:12248.","journal-title":"Sci Rep."},{"key":"1553_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110174","volume":"37","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Gu L, Lin X, Zhou X, Lu B, Liu C, et al. USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1. Cell Rep. 2021;37:110174.","journal-title":"Cell Rep."},{"key":"1553_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hep.31249","volume":"73","author":"L Gu","year":"2021","unstructured":"Gu L, Zhu Y, Lin X, Lu B, Zhou X, Zhou F, et al. The IKK\u03b2-USP30-ACLY axis controls lipogenesis and tumorigenesis. Hepatology. 2021;73:160\u201374.","journal-title":"Hepatology"},{"key":"1553_CR42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81184","volume":"12","author":"M Farrell","year":"2023","unstructured":"Farrell M, Fairfield H, Karam M, D\u2019amico A, Murphy CS, Falank C, et al. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling. Elife. 2023;12:e81184.","journal-title":"Elife"},{"key":"1553_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2022.107935","volume":"57","author":"C Deng","year":"2022","unstructured":"Deng C, Wu Y, Lv X, Li J, Liu Y, Du G, et al. Refactoring transcription factors for metabolic engineering. Biotechnol Adv. 2022;57:107935.","journal-title":"Biotechnol Adv"},{"key":"1553_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-0716-2815-7_9","volume":"2594","author":"Z Tao","year":"2023","unstructured":"Tao Z, Wu X. Targeting transcription factors in cancer: From \u201cundruggable\u201d to \u201cdruggable\u201d. Methods Mol Biol. 2023;2594:107\u201331.","journal-title":"Methods Mol Biol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01553-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01553-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01553-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:12:33Z","timestamp":1757160753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01553-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01553-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}